Takeda Pharmaceutical has won shareholder approval to finance its £46 billion (US$58.6 billion) purchase of Shire, paving the way for Japan’s largest corporate takeover and the creation of a global drugmaker with combined revenues of US$32 billion.
The vote on Wednesday, December 5, caps months of aggressive campaigning by Christophe Weber, Takeda’s CEO, to fend off attempts by founding family members to derail a deal that the 237-year-old group sees as pivotal to securing its place among the world’s top 10 pharmaceutical companies.
According to the Wall Street Journal, the acquisition propels 237-year-old Takeda into the big leagues, making the combined entity the world’s eighth-largest drugmaker by sales, and reflects how Japan’s corporate titans are looking abroad to fuel growth. Together, the companies would be estimated to earn half their revenue from the US, up from the roughly one-third that Takeda makes now. Takeda also estimates annual savings would reach at least US$1.4 billion three years after the merger.
Full Content: Wall Street Journal
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI